Literature DB >> 18279085

Evaluation of pathways for release of Rift Valley fever virus into domestic ruminant livestock, ruminant wildlife, and human populations in the continental United States.

Thomas R Kasari1, Deborah A Carr, Tracey V Lynn, J Todd Weaver.   

Abstract

OBJECTIVE: To evaluate the feasibility for Rift Valley fever virus (RVFV) to enter the continental United States by various routes as well as to identify states in which domestic and wild ruminant and human populations would be most vulnerable to exposure to RVFV. STUDY
DESIGN: Pathways analysis. SAMPLE POPULATION: Animals, commodities, and humans transported from RVFV-endemic countries to the continental United States between 2000 and 2005. PROCEDURES: Initially, agent, host, and environmental factors important in the epidemiologic aspects of RVFV were used to develop a list of potential pathways for release of RVFV into the continental United States. Next, the feasibility of each pathway was evaluated by use of data contained in governmental and public domain sources. Finally, entry points into the continental United States for each feasible pathway were used to identify the domestic and wild ruminant and human populations at risk for exposure to RVFV.
RESULTS: Feasible pathways for entry of RVFV into the continental United States were importation of RVFV-infected animals, entry of RVFV-infected people, mechanical transport of RVFV-infected insect vectors, and smuggling of live virus. CONCLUSIONS AND CLINICAL RELEVANCE: Domestic ruminant livestock, ruminant wildlife, and people in 14 states (Alabama, California, Florida, Georgia, Maine, Maryland, Massachusetts, Minnesota, New Jersey, New York, Pennsylvania, South Carolina, Texas, and Virginia) appeared to be most vulnerable to exposure to RVFV. Pathways analysis can provide the requisite information needed to construct an effective targeted surveillance plan for RVFV to enable rapid detection and response by animal health and public health officials.

Entities:  

Mesh:

Year:  2008        PMID: 18279085     DOI: 10.2460/javma.232.4.514

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  29 in total

1.  Risk assessment of the introduction of Rift Valley fever from the Horn of Africa to Yemen via legal trade of small ruminants.

Authors:  Shaif Abdo-Salem; Agnès Waret-Szkuta; François Roger; Marie-Marie Olive; Khalid Saeed; Véronique Chevalier
Journal:  Trop Anim Health Prod       Date:  2010-10-22       Impact factor: 1.559

Review 2.  Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.

Authors:  Colm Atkins; Alexander N Freiberg
Journal:  Future Virol       Date:  2017-10-23       Impact factor: 1.831

3.  Evaluation of the Efficacy, Potential for Vector Transmission, and Duration of Immunity of MP-12, an Attenuated Rift Valley Fever Virus Vaccine Candidate, in Sheep.

Authors:  Myrna M Miller; Kristine E Bennett; Barbara S Drolet; Robbin Lindsay; James O Mecham; Will K Reeves; Hana M Weingartl; William C Wilson
Journal:  Clin Vaccine Immunol       Date:  2015-06-03

4.  Coupling Vector-host Dynamics with Weather Geography and Mitigation Measures to Model Rift Valley Fever in Africa.

Authors:  B H McMahon; C A Manore; J M Hyman; M X LaBute; J M Fair
Journal:  Math Model Nat Phenom       Date:  2014-01-01       Impact factor: 4.157

5.  Emergence of zoonotic arboviruses by animal trade and migration.

Authors:  Martin Pfeffer; Gerhard Dobler
Journal:  Parasit Vectors       Date:  2010-04-08       Impact factor: 3.876

6.  Serological surveillance studies confirm the Rift Valley fever virus free status in South Korea.

Authors:  Hyun Joo Kim; Jee-Yong Park; Hye-Young Jeoung; Jung-Yong Yeh; Yun-Sang Cho; Jeong-Soo Choi; Ji-Youn Lee; In-Soo Cho; Han-Sang Yoo
Journal:  Trop Anim Health Prod       Date:  2015-05-30       Impact factor: 1.559

7.  Modelling vertical transmission in vector-borne diseases with applications to Rift Valley fever.

Authors:  Nakul Chitnis; James M Hyman; Carrie A Manore
Journal:  J Biol Dyn       Date:  2013       Impact factor: 2.179

8.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

9.  Cytokine response in mouse bone marrow derived macrophages after infection with pathogenic and non-pathogenic Rift Valley fever virus.

Authors:  Kimberly K Roberts; Terence E Hill; Melissa N Davis; Michael R Holbrook; Alexander N Freiberg
Journal:  J Gen Virol       Date:  2015-03-10       Impact factor: 3.891

10.  Inter-epidemic and between-season persistence of rift valley fever: vertical transmission or cryptic cycling?

Authors:  C A Manore; B R Beechler
Journal:  Transbound Emerg Dis       Date:  2013-03-28       Impact factor: 5.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.